Other Transaction Agreement W911QY2190008
Award Date
11/10/20
Potential Completion Date
9/29/26
Potential Value
$62M
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Ultimate Awardee
Not listed
NAICS Category
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Other
Place of Performance
Alachua, FL 32615, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $190,241,861.21 Other Transaction Agreement awarded by the Department of the Army's Joint PEO Chemical and Biological Defense to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company. The contract does not have a set-aside designation. The agreement, awarded on February 21, 2020, supports the development and manufacturing of medical countermeasures against biological threats and COVID-19. Resilience has provided...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., has been awarded a $162 million other transaction agreement by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to establish a COVID-19 prototype medical countermeasure manufacturing capability. The contract will support the development and production of medical countermeasures to combat COVID-19 and has a period of performance through August 2030. Nanotherapeutics will...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $5,107,357.36 Other Transaction Agreement to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., a technology-focused biomanufacturing company. The contract, which has no set-aside designation, is for the development of a "Plasmid Platform Protype" and is part of a larger $5.7 million Indefinite Delivery Vehicle aimed at transferring capabilities to...
This is a $6,821,012.21 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of a broad spectrum monoclonal antibody-based therapeutic for botulism, a biological threat. The contract has no set-aside designation and the ultimate completion date is September...
This federal contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) is valued at $9,080,310.52 and was issued by the Joint PEO Chemical and Biological Defense, part of the U.S. Department of the Army. The award is for drug substance process validation, drug product process validation, clinical development phase 3, and storage/stability activities to support the U.S. FDA licensure of the BONT MAB G03-52-01 drug product. The contract was awarded on March...
This is a prime contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services. The $14,898,362.53 cost-plus-fixed-fee contract is for biomedical research and development. It has a period of performance through December 31, 2011 and does not have a set-aside designation. Resilience Government Services is a technology-focused...
The U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded a $29,929,031.81 Other Transaction Agreement to Just-Evotec Biologics, Inc. to produce monoclonal antibody (mAb) product countermeasures against COVID-19. The contract, awarded on January 15, 2021, has an ultimate completion date of June 30, 2022 and is not set aside for any special business categories. Just-Evotec Biologics, Inc. is a for-profit, foreign-owned manufacturer of goods.
This is a $3,044,549.00 fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for biomedical research and development work, with a period of performance ending on March 31, 2010. No set-aside designations were used. Resilience Government Services, a technology-focused biomanufacturing company, has...
This is a federal contract award from the U.S. Army Medical Command (MEDCOM) to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., a technology-focused biomanufacturing company. The $970,700.00 Cost Plus Fixed Fee contract is for research and development work related to the Telemedicine and Advanced Technology Research Center (TATRC) program. The contract has no set-aside designation and has an ultimate completion date of September 30, 2013. Resilience Government...